Literature DB >> 29236215

Phylogenetic comparison of the VP7, VP4, VP6, and NSP4 genes of rotaviruses isolated from children in Nizhny Novgorod, Russia, 2015-2016, with cogent genes of the Rotarix and RotaTeq vaccine strains.

O V Morozova1,2, T A Sashina3, N V Epifanova3, V V Zverev3, A U Kashnikov3, N A Novikova3,4.   

Abstract

Group A rotaviruses (RVA) are one of the leading causes of gastroenteritis in young children worldwide. The introduction of universal mass vaccination around the world has contributed to a reduction in hospitalizations and outpatient visits associated with rotavirus infection. Continued surveillance of RVA strains is needed to determine long-term effects of vaccine introduction. In the present work, we carried out the analysis of the genotypic diversity of RVA strains isolated in Nizhny Novgorod (Russia) during the 2015-2016 epidemic season. Also we conducted a comparative analysis of the amino acid sequences of T-cell epitopes of wild-type and vaccine (RotaTeq and Rotarix) strains. In total, 1461 samples were examined. RVAs were detected in 30.4% of cases. Rotaviruses with genotype G9P[8] (40.5%) dominated in the 2015-16 epidemic season. Additionally, RVAs with the following genotypes were detected: G4P[8] (25.4%), G1P[8] (13%), G2P[4] (3.2%). Rotaviruses with genotypes G3P[9], G6P[9], and G1P[9] totaled 3%. The number of partially typed and untyped RVA samples was 66 (14.9%). The findings of a RVA of G6P[9] genotype in Russia were an original observation. Our analysis of VP6 and NSP4 T-cell epitopes showed highly conserved amino acid sequences. The found differences seem not to be caused by the immune pressure but were rather related to the genotypic affiliations of the proteins. Vaccination against rotavirus infection is not included in the national vaccination schedule in Russia. Monitoring of the genotypic and antigenic diversity of contemporary RVA will allow providing a comparative analysis of wild-type strains in areas with and without vaccine campaign.

Entities:  

Keywords:  Epidemiology; Epitopes; Rotavirus; Russia; Vaccines

Mesh:

Substances:

Year:  2017        PMID: 29236215     DOI: 10.1007/s11262-017-1529-9

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  64 in total

1.  Heterogeneity and temporal dynamics of evolution of G1 human rotaviruses in a settled population.

Authors:  Serenella Arista; Giovanni M Giammanco; Simona De Grazia; Stefania Ramirez; Concetta Lo Biundo; Claudia Colomba; Antonio Cascio; Vito Martella
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

2.  Prevalence and molecular characterization of G1P[8] human rotaviruses possessing DS-1-like VP6, NSP4, and NSP5/6 in Japan.

Authors:  Mitsutaka Kuzuya; Ritsushi Fujii; Masako Hamano; Koji Kida; Yoshinori Mizoguchi; Tomohisa Kanadani; Keiko Nishimura; Toshio Kishimoto
Journal:  J Med Virol       Date:  2013-09-16       Impact factor: 2.327

3.  Unipro UGENE: a unified bioinformatics toolkit.

Authors:  Konstantin Okonechnikov; Olga Golosova; Mikhail Fursov
Journal:  Bioinformatics       Date:  2012-02-24       Impact factor: 6.937

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 5.  Immunity to rotavirus infection in mice.

Authors:  M A Franco; H B Greenberg
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

6.  Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between human rotaviruses circulating in Belgium and rotaviruses in Rotarix and RotaTeq.

Authors:  Mark Zeller; John T Patton; Elisabeth Heylen; Sarah De Coster; Max Ciarlet; Marc Van Ranst; Jelle Matthijnssens
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

7.  Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium.

Authors:  Mark Zeller; Mustafizur Rahman; Elisabeth Heylen; Sarah De Coster; Sofie De Vos; Ingrid Arijs; Luis Novo; Natasha Verstappen; Marc Van Ranst; Jelle Matthijnssens
Journal:  Vaccine       Date:  2010-09-17       Impact factor: 3.641

8.  Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity.

Authors:  J W Burns; M Siadat-Pajouh; A A Krishnaney; H B Greenberg
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

9.  Emergence of a novel equine-like G3P[8] inter-genogroup reassortant rotavirus strain associated with gastroenteritis in Australian children.

Authors:  Daniel Cowley; Celeste M Donato; Susie Roczo-Farkas; Carl D Kirkwood
Journal:  J Gen Virol       Date:  2015-11-20       Impact factor: 3.891

10.  The epidemiology of all-cause and rotavirus acute gastroenteritis and the characteristics of rotavirus circulating strains before and after rotavirus vaccine introduction in Yemen: analysis of hospital-based surveillance data.

Authors:  Salem M Banajeh; Basheer A Abu-Asba
Journal:  BMC Infect Dis       Date:  2015-10-13       Impact factor: 3.090

View more
  3 in total

1.  Increasing detection of rotavirus G2P[4] strains in Nizhny Novgorod, Russia, between 2016 and 2019.

Authors:  Olga V Morozova; Tatiana A Sashina; Natalia V Epifanova; Alexander Yu Kashnikov; Nadezhda A Novikova
Journal:  Arch Virol       Date:  2020-10-20       Impact factor: 2.574

2.  Highly conserved epitopes of DENV structural and non-structural proteins: Candidates for universal vaccine targets.

Authors:  Mansi Verma; Shradha Bhatnagar; Kavita Kumari; Nidhi Mittal; Shivani Sukhralia; Shruthi Gopirajan At; P S Dhanaraj; Rup Lal
Journal:  Gene       Date:  2019-02-08       Impact factor: 3.688

3.  Prevalence and Genetic Diversity of Group A Rotavirus Genotypes in Moscow (2019-2020).

Authors:  Anton Yuzhakov; Ksenia Yuzhakova; Nadezhda Kulikova; Lidia Kisteneva; Stanislav Cherepushkin; Svetlana Smetanina; Marina Bazarova; Anton Syroeshkin; Tatiana Grebennikova
Journal:  Pathogens       Date:  2021-05-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.